Spring Bank Pharmaceuticals (NASDAQ: SBPH) is one of 298 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Spring Bank Pharmaceuticals to related businesses based on the strength of its risk, dividends, institutional ownership, valuation, profitability, analyst recommendations and earnings.

Profitability

This table compares Spring Bank Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Spring Bank Pharmaceuticals N/A -74.73% -47.49%
Spring Bank Pharmaceuticals Competitors -5,409.43% -437.09% -41.74%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Spring Bank Pharmaceuticals and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spring Bank Pharmaceuticals 0 1 3 0 2.75
Spring Bank Pharmaceuticals Competitors 769 3079 11289 227 2.71

Spring Bank Pharmaceuticals presently has a consensus target price of $26.33, indicating a potential upside of 67.41%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 25.38%. Given Spring Bank Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Spring Bank Pharmaceuticals is more favorable than its peers.

Institutional & Insider Ownership

28.2% of Spring Bank Pharmaceuticals shares are held by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 17.6% of Spring Bank Pharmaceuticals shares are held by insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Spring Bank Pharmaceuticals has a beta of 2.59, suggesting that its stock price is 159% more volatile than the S&P 500. Comparatively, Spring Bank Pharmaceuticals’ peers have a beta of 6.53, suggesting that their average stock price is 553% more volatile than the S&P 500.

Valuation & Earnings

This table compares Spring Bank Pharmaceuticals and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Spring Bank Pharmaceuticals $350,000.00 -$17.36 million -5.72
Spring Bank Pharmaceuticals Competitors $290.00 million $35.57 million -5.05

Spring Bank Pharmaceuticals’ peers have higher revenue and earnings than Spring Bank Pharmaceuticals. Spring Bank Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Spring Bank Pharmaceuticals Company Profile

Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases. The Company’s SB 9200 selectively activates within infected cells the cellular proteins retinoic acid-inducible gene 1 (RIG-I) and nucleotide-binding oligomerization domain-containing protein 2 (NOD2) to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. The Company is also developing a second SMNH product candidate, SB 11285, as an immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of INterferon Genes (STING) pathway. The Company focuses on developing SB 9200 for the treatment of chronic hepatitis B virus (HBV).

Receive News & Ratings for Spring Bank Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.